secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001493152-22-021966
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q2 net loss $12.1M; cash runway to 2Q 2023; VIITAL data expected late Q3/early Q4
--------------------------------------------------------------------------------

- Net loss $12.1M ($2.08 loss/share) vs $15.2M ($3.93 loss/share) in Q2 2021.
- Cash and investments $26.0M; net cash used in ops $9.0M; runway extended into Q2 2023.
- License revenue $1.0M from Taysha sublicense milestone; R&D $6.7M, G&A $3.5M.
- Phase 3 VIITAL study for EB-101 topline data expected late Q3/early Q4 2022; last patient monitoring mid-September.
- License agreement with Ultragenyx for ABO-102 (MPS IIIA); Abeona eligible for tiered royalties and milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315222021966/0001493152-22-021966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315222021966/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-021966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer